US Patent 10,857,102: Scope, Claim Construction, and Rilpivirine/Emtricitabine/Tenofovir Patent Landscape

US Patent 10,857,102 protects narrowly defined multilayer tablets containing rilpivirine hydrochloride, emtricitabine, and tenofovir disoproxil fumarate. The claims are formulation-specific rather than compound claims. Their commercial target is the fixed-dose antiretroviral combination marketed as Complera in the United States and Eviplera in Europe.

The strongest claim limitation is the required composition and quantity of each tablet layer. A competing product that changes an excipient, materially changes an amount, uses a different layer structure, or omits the specified film coating may avoid literal infringement, although the doctrine of equivalents remains relevant. The patent does not broadly cover every tablet containing rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

What drug product does US Patent 10,857,102 protect?

The patent covers a fixed-dose tablet containing:

Active ingredient	Claimed amount
Rilpivirine hydrochloride	27.5 mg
Emtricitabine	200.0 mg
Tenofovir disoproxil fumarate	300.0 mg

These strengths correspond to the active-ingredient composition of Complera, approved by the FDA in 2011 for treatment of HIV-1 infection in appropriate patients [2].

The patent's formulation architecture separates rilpivirine from emtricitabine and tenofovir disoproxil fumarate. Rilpivirine occupies one layer, while emtricitabine and tenofovir disoproxil fumarate occupy another. The separation is technically relevant because rilpivirine has distinct formulation and dissolution requirements from the nucleoside/nucleotide reverse-transcriptase inhibitors.

The patent is assigned to Gilead Sciences, Inc., based on the published patent record [1].

What are the independent claims of US 10,857,102?

Claims 1, 2, and 3 are the principal independent claims.

Claim 1: Two-layer tablet

Claim 1 requires a tablet with two layers.

First layer

The first layer must consist of:

Component	Amount
Rilpivirine HCl	27.5 mg
Microcrystalline cellulose	60.0 mg
Lactose monohydrate	189.8 mg
Povidone	3.3 mg
Polysorbate 20	0.4 mg
Croscarmellose sodium	16.1 mg
Magnesium stearate	3.0 mg

The calculated first-layer weight is 300.1 mg.

Second layer

The second layer must consist of:

Component	Amount
Emtricitabine	200.0 mg
Tenofovir disoproxil fumarate	300.0 mg
Microcrystalline cellulose	150.0 mg
Lactose monohydrate	80.0 mg
Pregelatinized starch	50.0 mg
Croscarmellose sodium	60.0 mg
Magnesium stearate	10.0 mg

The calculated second-layer weight is 850.0 mg.

The total uncoated tablet weight under claim 1 is therefore approximately 1,150.1 mg.

Claim 2: Three-layer tablet with separating layer

Claim 2 requires the same rilpivirine-containing first layer and the same emtricitabine/tenofovir-containing second layer, but adds a third layer between them.

The third layer must comprise 150 ± 8.0 mg of:

microcrystalline cellulose;
lactose monohydrate; or
a mixture of the two.

The permitted third-layer weight is 142.0 mg to 158.0 mg. Its function is structural separation between the two active-containing layers.

The total uncoated tablet weight under claim 2 is approximately 1,292.1 mg to 1,308.1 mg, depending on the third-layer weight.

Claim 3: Two-layer tablet with a defined film-coating weight

Claim 3 covers the same two active-containing layers but requires 34.5 mg of film coating.

The coating composition is not specified in the independent claim. This creates a different infringement profile from claim 5, which requires a hydrophilic polymer material.

The total coated tablet weight under claim 3 is approximately 1,184.6 mg.

The supplied wording of claim 3 states "60.0 microcrystalline cellulose" without a mass unit. In context, the limitation appears to correspond to the 60.0 mg microcrystalline cellulose limitation in claims 1 and 2. The issued patent should control for claim construction.

How should the "consists of" language be interpreted?

The word "consists of" materially narrows the claims.

In U.S. patent interpretation, "consists of" generally excludes unlisted ingredients or structural elements that materially alter the claimed composition. By contrast, "comprising" is open-ended and ordinarily permits additional components [3].

For these claims, the distinction creates several design-around opportunities:

Formulation change	Literal-infringement risk
Replace lactose with mannitol	Lower
Replace povidone with hypromellose	Lower
Change 0.4 mg polysorbate 20 to another surfactant	Lower
Add an unlisted excipient to a claimed layer	Potentially significant
Change the rilpivirine amount	Lower for literal infringement
Move an excipient to another layer	Lower if layer identity changes
Use a single homogeneous layer	Lower against claims 1-3
Use a three-layer tablet without the claimed 150 ± 8 mg separator	Lower against claim 2
Use a coating with a different weight	Lower against claim 3
Use a non-hydrophilic coating	Lower against claim 5

The doctrine of equivalents could still apply where a formulation change performs substantially the same function in substantially the same way to achieve substantially the same result. Prosecution-history estoppel, claim amendments, and prior-art distinctions may limit that theory [3].

What formulations are protected by the dependent claims?

What does claim 4 add?

Claim 4 depends on claim 1 and requires a film coating. It therefore covers the exact two-layer composition in claim 1 with a film coating of unspecified composition and weight.

Claim 4 is broader than claim 3 in one respect because it does not specify a 34.5 mg coating weight. It is narrower than claim 1 because an uncoated tablet would not satisfy the added limitation.

What does claim 5 add?

Claim 5 depends on claim 4 and requires that the film coating comprise a hydrophilic polymer material.

Potential hydrophilic coating polymers may include materials such as:

hypromellose;
hydroxypropyl cellulose;
polyvinyl alcohol;
polyethylene glycol-containing coating systems; and
other water-compatible polymeric film formers.

The patent claim should be read against its specification and prosecution record. The generic phrase "hydrophilic polymer material" does not automatically cover every hydrophilic coating ingredient or every polymer used in an aqueous coating system.

How strong is the patent estate for Complera?

The commercial product is protected by several distinct categories of intellectual property, but US 10,857,102 is concentrated in the finished dosage form.

Protection category	Relevance to Complera
Rilpivirine compound patents	Protect the active pharmaceutical ingredient or related chemical forms
Combination-product patents	Protect coadministration or fixed-dose combinations
Formulation patents	Protect layer composition, excipients, coating, and tablet architecture
Method-of-use patents	Protect treatment of HIV-1 under specified dosing or patient conditions
Regulatory exclusivity	Provides time-limited FDA protection separate from patent rights
Manufacturing know-how	May protect compression sequence, segregation control, blending, coating, and scale-up parameters

US 10,857,102 is strongest against a generic that copies the specified Complera formulation. It is materially weaker against a product that uses the same three active ingredients but adopts a different formulation strategy.

The patent does not, on its face, claim:

rilpivirine as a chemical compound;
emtricitabine as a chemical compound;
tenofovir disoproxil fumarate as a chemical compound;
all fixed-dose combinations of the three ingredients;
every multilayer tablet containing the three ingredients;
a method of treating HIV using the combination; or
a manufacturing process for producing the tablet.

When does US 10,857,102 lose exclusivity?

The patent's enforceable term depends on the earliest effective nonprovisional priority date, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension. A grant date alone does not establish the expiration date.

US 10,857,102 issued on December 8, 2020 [1]. The relevant expiration date must be taken from the USPTO patent record and any current Orange Book listing. Patent-term adjustment can extend the ordinary 20-year term, while a terminal disclaimer can eliminate or limit adjustment [4].

The patent should be analyzed in parallel with:

the listed patent expiration date in the FDA Orange Book;
the patent's USPTO maintenance-fee status;
any terminal disclaimer;
any later-issued continuation or divisional patents; and
any regulatory exclusivity applicable to the reference listed drug.

Patent expiration and FDA exclusivity are separate. Expiration of this patent does not necessarily eliminate other blocking rights, and the expiration of another patent does not eliminate this patent.

What is the Orange Book status of US 10,857,102?

The FDA Orange Book is the operative source for determining whether a patent is listed against a specific approved drug product and whether it has been submitted under an FDA patent-listing category [5].

A patent number alone does not establish:

that the patent is listed against Complera;
which approved strength or dosage form it covers;
whether the listing is for a drug substance, drug product, or method of use;
whether the listing remains active;
whether a patent-use code applies; or
whether an ANDA applicant must make a Paragraph IV certification.

The relevant Orange Book inquiry should distinguish Complera from other rilpivirine-containing products. Edurant contains rilpivirine alone. Odefsey contains emtricitabine, rilpivirine, and tenofovir alafenamide, not tenofovir disoproxil fumarate. Juluca contains rilpivirine and dolutegravir. A patent directed to the Complera formulation does not automatically cover those products.

What Paragraph IV risks apply to a generic applicant?

A generic applicant seeking approval for the same fixed-dose combination may need to address listed patents through one of four certifications under the Hatch-Waxman framework:

Certification	Effect
Paragraph I	No patent information has been submitted
Paragraph II	Listed patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Patent is invalid, unenforceable, or will not be infringed

A Paragraph IV notice can trigger patent litigation under 21 U.S.C. § 355(j)(5)(B)(iii). A timely infringement action may impose a 30-month stay of FDA approval, subject to statutory exceptions and court events [6].

For this patent, a generic applicant could pursue several technical positions:

the proposed tablet does not have the claimed layer composition;
one or more ingredient quantities fall outside the claim;
the product lacks the claimed separator layer;
the product has no film coating or a coating outside the relevant dependent claim;
the patent is invalid for anticipation or obviousness;
the claims are indefinite because of ingredient identity, quantity, or coating terminology; or
the claims are unenforceable based on prosecution or conduct issues.

The formulation's highly specific quantities help an applicant formulate a noninfringing alternative. They also make an anticipation or obviousness analysis fact-intensive because the complete combination of ingredients, quantities, layer arrangement, and coating limitations must be assessed as a whole.

Which companies are challenging the Complera patent estate?

A reliable company-by-company challenge analysis requires current PACER, FDA ANDA, Orange Book, and USPTO data. The supplied patent and claims do not identify an ANDA filer, Paragraph IV notice, litigation docket, settlement, or license.

No specific challenger, litigation outcome, or settlement should be attributed to US 10,857,102 without a docket or FDA record. The absence of a cited challenger in the patent record does not establish that no challenge has occurred.

What litigation issues are most important?

A dispute involving these claims would likely focus on five issues.

Exact composition

The use of "consists of" makes the identity and quantity of each excipient central. Batch records, master manufacturing records, certificates of analysis, and finished-product testing could become relevant.

Layer allocation

An accused product could contain all of the same ingredients but assign them to different layers. The claim requires specific ingredient-to-layer allocation.

Quantity tolerances

Claims 1, 2, and 3 state fixed quantities for most ingredients. Claim 2 expressly provides a ±8.0 mg tolerance only for the third layer. That express tolerance may support an argument that other quantities lack an equivalent explicit range.

Coating limitations

Claim 3 requires 34.5 mg of film coating. Claim 4 requires a film coating without a stated mass. Claim 5 adds the hydrophilic-polymer limitation. Coating weight, composition, and measurement method could therefore become disputed.

Invalidity

The most credible prior-art search targets are:

earlier Complera formulation disclosures;
regulatory submissions or product labels;
patent applications covering rilpivirine combinations;
multilayer tablet references;
pharmaceutical excipient-combination references; and
manufacturing development documents made public before the earliest priority date.

A reference must disclose every limitation for anticipation. Obviousness would require a legally sufficient reason to combine the relevant disclosures with a reasonable expectation of success.

How does US 10,857,102 compare with Odefsey and other rilpivirine products?

Product	Active ingredients	Relationship to US 10,857,102
Complera	Emtricitabine, rilpivirine, tenofovir disoproxil fumarate	Direct commercial target
Eviplera	Same three actives, marketed outside the U.S.	Same active combination; jurisdictional patent rights differ
Edurant	Rilpivirine alone	Not covered by the complete combination claims
Odefsey	Emtricitabine, rilpivirine, tenofovir alafenamide	Different tenofovir prodrug
Juluca	Rilpivirine and dolutegravir	Lacks emtricitabine and tenofovir disoproxil fumarate

Odefsey is particularly important competitively because it replaces tenofovir disoproxil fumarate with tenofovir alafenamide. That substitution generally avoids a claim requiring tenofovir disoproxil fumarate, although separate Odefsey patents and regulatory protections apply.

What generic launch scenarios exist?

Scenario 1: Formulation copy

A generic copies the two-layer Complera composition. This presents the highest infringement risk under claim 1 and potentially claims 4 and 5.

Scenario 2: Three-layer design

A generic uses a separator layer between rilpivirine and the emtricitabine/tenofovir layer. Claim 2 becomes relevant if the separator contains 142 mg to 158 mg of the specified cellulose/lactose materials.

Scenario 3: Excipient substitution

A generic substitutes one or more excipients or changes the quantities. This is the most direct design-around path, subject to bioequivalence, dissolution, stability, and formulation constraints.

Scenario 4: Single-layer tablet

A homogeneous tablet may avoid the express multilayer limitations but could create manufacturing and dissolution problems because rilpivirine is physically combined with the other active ingredients.

Scenario 5: Alternative tenofovir product

A product containing tenofovir alafenamide rather than tenofovir disoproxil fumarate is outside the literal active-ingredient requirement of these claims. It would be evaluated under a separate patent estate.

Key Takeaways

US 10,857,102 is a formulation patent directed to Complera-type tablets.
The claims require rilpivirine HCl, emtricitabine, and tenofovir disoproxil fumarate in specified layers and quantities.
Claims 1 and 3 cover two-layer tablets; claim 2 covers a three-layer tablet with a defined separator layer.
Claims 4 and 5 add film-coating limitations.
The "consists of" language creates a relatively narrow literal scope.
The patent does not broadly claim the three active ingredients, all rilpivirine combinations, or all HIV treatment methods.
Odefsey, Edurant, and Juluca have materially different active-ingredient compositions.
Generic risk depends heavily on Orange Book listing status, the patent's effective expiration date, the proposed generic formulation, and any Paragraph IV litigation.
The patent's exact expiration date cannot be determined from the claims alone because priority, terminal-disclaimer, and patent-term-adjustment records control.

FAQs

Does US 10,857,102 cover all Complera tablets?

It covers tablets that satisfy the claimed layer composition and quantity limitations. A Complera tablet with a materially different formulation may not satisfy every claim limitation.

Can a generic use the same active ingredients with different excipients?

Possibly. A generic can reduce literal infringement risk by changing excipient identity, quantity, layer allocation, tablet architecture, or coating. It must still satisfy FDA bioequivalence and product-quality requirements.

Does the patent cover Odefsey?

Not literally based on the supplied claims. Odefsey contains tenofovir alafenamide, while these claims require tenofovir disoproxil fumarate.

Is claim 2 broader than claim 1?

No. Claim 2 adds a separating third layer and therefore imposes additional structural limitations. It may cover a different tablet architecture, but it is not broader than claim 1 in claim scope.

Does patent expiration automatically permit generic launch?

No. Launch timing also depends on other unexpired patents, Orange Book listings, FDA exclusivity, litigation stays, settlements, injunctions, and regulatory approval.

References

U.S. Patent No. 10,857,102, Pharmaceutical composition comprising rilpivirine, issued Dec. 8, 2020. United States Patent and Trademark Office. https://patents.google.com/patent/US10857102B2
U.S. Food and Drug Administration. (2011). Complera prescribing information. https://www.accessdata.fda.gov
U.S. Supreme Court. (1997). Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 520 U.S. 17.
United States Code. 35 U.S.C. §§ 154, 156, and 253.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
United States Code. 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	November 18, 2011	PCT Application Number:	PCT/US2011/061515
PCT Publication Date:	May 24, 2012	PCT Publication Number:	WO2012/068535

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3816	⤷ Start Trial
Argentina	084500	⤷ Start Trial
Argentina	123409	⤷ Start Trial
Australia	2011329642	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 10,857,102